v3.25.2
Organization and Nature of Business and Basis of Presentation - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 23, 2024
May 31, 2025
Apr. 30, 2025
Dec. 31, 2024
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Net loss         $ (7,585) $ (6,077) $ (6,259) $ (22,314) $ (13,662) $ (28,573) $ (36,568) $ (21,148)
Cash in operating activities                 (19,131) (15,138) (21,319) (18,233)
Accumulated deficit       $ (179,900) (197,518)       (197,518)   (179,900) (143,332)
Cash and cash equivalents       12,118 6,021       6,021   12,118 15,321
Merger Agreement [Member]                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Gross proceeds $ 75,000                      
Loan Agreement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Debt instrument, face amount $ 22,500                      
Debt instrument, interest rate, stated percentage 6.00%                      
Term loans $ 7,500                      
Inmagene [Member] | Loan Agreement | Merger Agreement [Member]                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Debt instrument, face amount $ 22,500                      
Debt instrument, interest rate, stated percentage 6.00%                      
Term loans $ 7,500                      
IKENA ONCOLOGY INC                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Net loss         (2,767) $ (8,619) (13,730) $ (16,146) (11,386) (29,876) (49,234) (68,166)
Cash in operating activities                 (13,984) (30,806) (46,004) (79,743)
Accumulated deficit       (331,619) (343,005)       (343,005)   (331,619) (282,385)
Cash and cash equivalents       39,393 58,290   $ 44,268   58,290 $ 44,268 39,393 119,894
Gross proceeds                       $ 37,421
Amounts loaned under note receivable                 $ 15,000   7,500  
IKENA ONCOLOGY INC | Inmagene [Member] | Loan Agreement | Merger Agreement [Member]                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Loan amount 22,500                      
Amounts loaned under note receivable   $ 7,500 $ 7,500 $ 7,500 $ 15,000           7,500  
IKENA ONCOLOGY INC | Inmagene [Member] | Loan Agreement | Merger Agreement [Member] | Maximum [Member]                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Loan amount $ 22,500                   $ 22,500